, assisted and supported the execution of such trading transactions. This case is in the process of inquiry by the special case inquiry official. SEC Act S.307 311 in conjunction with 315 Criminal Complaint

million baht, which created an unlawful benefit for Mr. Bhusana. Miss Ploykaew, Miss Kornrawan Sunprasert and Mr. Nanthawat Bhudithaiyarasak, who were ESES director, assisted and supported the execution of

Company Limited (ESES) director, assisted and supported the execution of such trading transactions. This case is in the process of inquiry by the special case inquiry official. SEC Act S.307 311 in

2017 PERFORMANCE ANALYSIS (YoY) In 3Q 2017, the Company once again achieved an outstanding top and bottom line performance compared to the same quarter last year supported by; 1) The consolidation of

, medical device business is expected to be growth at an average rate of 8.5-10.0% per year. This growth will be supported by: (i) government policy, focused on promoting investment in the sector through the

169 million. Dusit Thani PCL Management Discussion and Analysis For 1Q18 P a g e | 6 *Annualized ** = EBIT/ Interest expense The Company’s profitability remained resilient in 1Q18, showing improved

expected to be growth at an average rate of 8.5-10.0% per year. This growth will be supported by: (i) government policy, focused on promoting investment in the sector through the offering of special

key driver with continued growth across all categories supported by the increased in farm income both in productions and prices. Exports during the first five months of 2019 contracted 2.3% from the

continued growth across all categories supported by the increased in farm income both in productions and prices. Exports during the first half of 2019 contracted 2.9% from the same period last year as a

(27,835) - (27,835) 100 Gross Profit 48,521 32,045 16,476 192 Other Income 5,417 2,724 2,693 99 Profit before Expense 53,938 34,769 19,169 55.13 Sale Expense (5,681) (3,186) (2,495) 78.31 Administrative